We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Since 2008, there has been no “consistent increase” in ...

Patients who require biologic disease-modifying antirheumatic drugs (DMARDs) for severe RA are less likely to achieve sustained DMARD-free remission than those not needing the medication. Patients ...

Please provide your email address to receive an email when new articles are posted on . Biologic disease-modifying antirheumatic drugs used to treat juvenile rheumatic diseases are excluded entirely ...

Biologics are more effective at treating adult-onset Still’s disease (AOSD) than are glucocorticoids or conventional disease-modifying antirheumatic drugs (DMARDs), according to a new retrospective ...

The rheumatoid arthritis therapeutics market is set for growth driven by innovative biosimilars like Cyltezo and Hyrimoz, ...

In recent years, the treatment of rheumatic inflammatory diseases has been revolutionized. With the advent of biologic and targeted synthetic disease-modifying antirheumatic drugs (DMARDs), minimal ...

Patients with adult-onset Still's disease were much more likely to achieve sustained remission when they were initially treated with biologic agents than corticosteroids or conventional ...

Biologic disease-modifying antirheumatic drugs (DMARDs) such as adalimumab, etanercept and infliximab are effective at reducing symptoms and slowing progression of rheumatoid arthritis (RA). These ...

A study looked at more than 23,600 Medicare beneficiaries with RA who had received a ≥30-day prescription of an opioid drug. Participants were grouped according to those who had been prescribed a ...

Researchers at University of Texas Release New Data on Rheumatoid Arthritis (Examining Time to Initiation of Biologic Disease-modifying Antirheumatic Drugs and Medication Adherence and Persistence ...

Managing symptoms of rheumatoid arthritis may require trying different medicines to see what works best for you and your symptoms. The approval of Xeljanz has led to changes in how rheumatoid ...